AbbVie’s alliance with Gilgamesh Pharmaceuticals is pursuing next-generation psychiatric medications. The companies aim to bring patients drugs that offer the benefit of psychedelics but with a better side effect profile.
The post AbbVie Expands Psychiatric Drug Prospects, Inking R&D Pact With Neuroscience Startup appeared first on MedCity News.
Related Articles
How Should Healthcare Startups Approach Employers? 3 Execs Weigh In
During a panel at the MedCity News INVEST Digital Health conference, three...
As Medicaid Unwinding Concludes in Most States, KFF Finds 25 Million Lost Medicaid Coverage but Enrollment is 10 Million Higher Than Pre-Pandemic Levels
Over 25 million people were disenrolled from Medicaid and over 56 million...
Cultural Competence in Medical Tourism
Cultural sensitivity is a key factor when treating visitors from other nations...
Reporting Checklist for Discrete Choice Experiments in Health
What are the key elements for reporting your objective, attributes, experimental design,...
Leave a comment